ARA-290: Molecular Structure

Molecular Structure and Properties#

ARA-290 (cibinetide) is an 11-amino acid linear peptide with a molecular weight of approximately 1,257 Da. It was rationally designed from the three-dimensional structure of erythropoietin (EPO), specifically from the outer aqueous face of helix B, which mediates tissue-protective signaling through the innate repair receptor.

Amino Acid Sequence#

The primary sequence of ARA-290 is Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (QEQLERALNSS). This 11-residue sequence corresponds to positions on the B helix of EPO that form part of the binding interface with the innate repair receptor (IRR) but do not contribute to binding with the classical EPO receptor homodimer.

Design Rationale#

The peptide was designed based on structural studies that identified two distinct receptor-binding faces on EPO. The high-affinity site (Site 1) primarily mediates classical EPOR homodimer binding and erythropoiesis. The lower-affinity site (Site 2), located on the opposite face of the molecule including the B helix, mediates binding to the IRR complex (EPOR-betacR heteromer). By extracting a peptide sequence from Site 2 only, ARA-290 selectively activates the IRR without triggering erythropoietic signaling.

Physicochemical Properties#

Receptor Binding Characteristics#

Innate Repair Receptor (IRR)#

ARA-290 binds with low nanomolar affinity to the innate repair receptor, a heteromeric complex of the erythropoietin receptor (EPOR) and the beta common receptor (CD131). This receptor is not constitutively expressed at high levels under normal conditions but is upregulated at sites of tissue injury and inflammation.

The selective binding of ARA-290 to the IRR over the classical EPOR homodimer is the key pharmacological feature that distinguishes it from EPO. EPO binds both receptor complexes, leading to both erythropoietic and tissue-protective effects. ARA-290 binds only the IRR, providing tissue protection without erythropoiesis.

Binding Kinetics#

Despite a short plasma half-life of approximately 2 minutes, ARA-290 triggers sustained biological effects that persist well beyond its circulating presence. This is attributed to the receptor-mediated signaling cascade: once the IRR is activated, downstream signaling through JAK2-STAT5 and PI3K-Akt pathways continues for hours, even after the peptide has been cleared from circulation.

Pharmacokinetic Profile#

Absorption#

ARA-290 has been administered both intravenously and subcutaneously in clinical trials. The subcutaneous route provides adequate bioavailability for therapeutic effect, as demonstrated in clinical trials where daily subcutaneous injection of 4 mg produced measurable neuroprotective outcomes.

Distribution#

The peptide distributes rapidly from the bloodstream to tissues. Its small size (1,257 Da) allows passage across the blood-nerve barrier, enabling direct access to peripheral nerve tissues. Distribution to the central nervous system has been demonstrated in preclinical models.

Metabolism and Elimination#

ARA-290 undergoes rapid proteolytic degradation in plasma, consistent with its short half-life of approximately 2 minutes. The peptide is broken down by standard peptidases and aminopeptidases. Despite this rapid clearance, the triggering of sustained intracellular signaling cascades means that daily or thrice-weekly dosing is sufficient for therapeutic effect.

Stability and Formulation#

ARA-290 is stable in standard pharmaceutical formulations suitable for injection. In clinical trials, it has been formulated as a sterile aqueous solution for intravenous and subcutaneous administration. The peptide does not require specialized cold-chain storage conditions for the formulated drug product, though the bulk peptide is typically stored at -20 degrees Celsius.

Comparison with Erythropoietin#

The small size of ARA-290 compared to full-length EPO provides advantages in manufacturing (chemical synthesis vs. recombinant production), reduced immunogenicity, and elimination of erythropoietic side effects. The tradeoff is a dramatically shorter plasma half-life, necessitating more frequent dosing.

Related Reading#

• ARA-290 overview and research guide
• Peptides similar to ARA-290
• ARA-290 research evidence